secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2023-06-21T23:59:59+00:00
Accession:  0001171843-23-004058
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika appoints Anne Nunes as SVP, COO; shareholders approve 435K-share plan increase
--------------------------------------------------------------------------------

- Anne Nunes appointed SVP, Chief Operations Officer effective June 19, 2023; base salary $440,000, target bonus 45%.
- Stockholders approved amendment increasing 2017 Plan share reserve by 435,000 to 5,285,000 shares.
- Gary Fischetti, John Henneman, and Susan Vogt elected Class III directors until 2026 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184323004058/0001171843-23-004058-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184323004058/f8k_062123.htm
  HTML page:      https://secwatch.observer/filing/0001171843-23-004058

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer